Novacyt SAS

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010397232
EUR
0.43
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Novacyt SAS stock-summary
stock-summary
Novacyt SAS
Pharmaceuticals & Biotechnology
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
Company Coordinates stock-summary
Company Details
13 avenue Morane Saulnier , VELIZY VILLACOUBLAY None : 78140
stock-summary
Tel: 33 1 3946510444 7901 514121
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Wakefield
Independent Non-Executive Chairman
Mr. Graham Mullis
Chief Executive Officer, Executive Director, Member of the Executive Team
Mr. Anthony Dyer
Chief Corporate Development Officer, Executive Director
Mr. Jean-Pierre Crinelli
Non-Executive Director
Dr. Andrew Heath
Independent Senior Non-Executive Director
Dr. Edwin Snape
Independent Non-Executive Director
Ms. Juliet Thompson
Independent Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 31 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.56

stock-summary
Return on Equity

-37.45%

stock-summary
Price to Book

0.65